News

Targeted Oncology22h
FDA Receives Vepdegestrant NDA for ESR1-Mutated Breast Cancer
A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...
Market Inference12h
Arvinas, Inc. Submits NDA for Vepdegestrant
Arvinas, Inc. (NASDAQ: ARVN) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...